Cell and Gene Therapy Becomes a Hospital Operations Test
Cell and gene therapies are often described as a scientific frontier. For many hospitals, the more immediate frontier is operational. As these treatments move beyond a small number of specialist centres into broader clinical use, the limiting factor is less often the underlying science than the health system’s ability to collect, track, prepare, deliver and monitor a therapy that behaves unlike an ordinary medicine.
That distinction matters because cell and gene therapies do not fit neatly into established hospital workflows. Some are autologous, built from a patient’s own cells, which means the patient is both source and recipient. Others use donor-derived cells or direct genetic modification. In either case, the hospital becomes part of a chain that extends beyond its walls, involving manufacturers, couriers, laboratories, pharmacies, apheresis units, infusion suites and clinical teams. Each handoff creates a point of failure that cannot be managed by procurement alone.
The 2026 Global Healthcare Awards’ interest in practical innovation, safety and accountable delivery reflects this shift. The question is not only whether a therapy is approved or clinically promising. It is whether a provider can deliver it reliably, equitably and with auditable controls. That makes cell and gene therapy a test of hospital operations.
Chain of Identity Is a Clinical Safety Control
For autologous therapies, the chain begins with collection. A patient’s cells are harvested, labelled, cryopreserved and shipped to a manufacturing site before being returned for infusion. The process depends on a chain of identity and a chain of custody that remain intact from bedside to laboratory, from laboratory to courier, and from manufacturer back to the patient.
This is not a clerical exercise. A mislabelled sample, a missed handoff or an ambiguous custody record can delay treatment, waste a manufacturing slot or create a serious safety risk. Hospitals need standardised labelling, independent verification, temperature and location tracking, and clear rules for who may release a product at each stage. Scheduling discipline matters as well: collection, manufacturing slots, shipping windows and infusion appointments must align across departments that may not traditionally work as one team.
Auditability is part of the control. When a regulator, manufacturer or internal reviewer asks what happened to a patient’s cells at a particular point, the hospital should be able to show the record rather than reconstruct it from memory. That requires information systems and paper processes to be designed around the therapy pathway, not bolted on afterwards.
Capacity Planning Goes Beyond Drug Procurement
A hospital can have a therapy approved, a manufacturer contract signed and a clinician ready to prescribe, and still be unable to scale. The constraint may be an apheresis chair, an infusion bed, a laboratory turnaround time, a cryopreservation tank or a courier route. Cell and gene therapy capacity is a network of physical and human resources, not a single purchasing decision.
Apheresis units need trained staff, suitable equipment and enough scheduled time to collect cells without displacing other patients. Infusion suites need beds and nursing capacity for therapies that may require close observation. Laboratories need processes for handling and testing cellular products, and pharmacy teams need workflows for receipt, storage and release. Cryopreservation and logistics add another layer: storage space, temperature monitoring, chain-of-custody documentation and contingency plans for delays.
These dependencies make capacity planning a cross-functional exercise. A therapy that is clinically suitable for a patient may be operationally impossible that week because the collection slot, manufacturing date and infusion bed do not line up. Hospitals that treat scheduling as an afterthought will find that growth is constrained by bottlenecks they did not measure.
Safety Requires Standard Work, Not Just Specialist Knowledge
Cell and gene therapies carry therapy-specific risks that can emerge quickly. Cytokine release syndrome and neurotoxicity are among the most discussed, but they are not the only concerns. Infection, prolonged cytopenias and other complications may require monitoring beyond the infusion visit. The hospital’s safety model must therefore extend across emergency departments, wards, intensive care and outpatient follow-up.
Standardised toxicity monitoring and escalation pathways are essential. That means agreed grading criteria, clear triggers for urgent review, accessible treatment protocols and nursing staff who can recognise deterioration. It also means planning for capacity in critical care and ensuring that on-call teams know which patients have received a recently administered therapy and what to do if they present unwell.
Education cannot be confined to the specialist team. Emergency clinicians, general ward nurses, pharmacists and laboratory staff may encounter these patients outside the original treatment centre. A single expert may be able to manage a complication in a specialist unit; a health system needs a repeatable process that works on a Saturday night in a hospital far from the prescribing centre.
Finance and Payer Coordination Shape Access
Cell and gene therapies are expensive and administratively complex. Payer authorisation, coverage rules and payment timing affect whether a patient can start treatment and whether the hospital can manage its cash flow. Finance teams are therefore central to therapy readiness, not peripheral to it.
Hospitals need clear processes for benefits verification, prior authorisation, appeals and patient financial support. They also need to understand when payment arrives relative to when the hospital incurs costs for collection, storage, infusion and follow-up. A therapy that is reimbursed eventually may still strain working capital if the hospital must carry significant costs in the interim.
Contracting adds another dimension. Manufacturers, payers and providers may have different expectations about data, outcomes reporting and payment arrangements. Hospitals that negotiate these details without operational input can find that the clinical pathway and the financial pathway do not match. Access also has an equity dimension: if authorisation depends on navigating a complex administrative process, patients with less support may be left behind.
Governance, Training and Follow-Up Determine Whether Scale Is Safe
Cell and gene therapy readiness is ultimately a governance problem. It requires a cross-functional group with authority to make decisions across pharmacy, apheresis, nursing, laboratories, information technology, finance and clinical leadership. That group needs to own the pathway, review incidents, track capacity and approve changes.
Workforce training must be ongoing. Staff need to understand not only the science but also the operational controls: how to verify identity, how to document handoffs, how to recognise toxicity and how to escalate. Training should be recorded and refreshed, and it should reach teams that may see these patients only occasionally.
Long-term follow-up data capture is another test. Regulators and manufacturers may require monitoring for delayed effects, and hospitals need systems that can identify and contact patients over time. That is difficult when patients move, change providers or receive care in different systems. Without deliberate follow-up, the hospital cannot demonstrate that it is delivering the therapy safely beyond the immediate treatment period.
The 2026 Global Healthcare Awards’ focus on practical innovation and accountable delivery is relevant here. The most credible programmes will not be those with the most advanced research portfolio alone, but those that can show reliable identity controls, realistic capacity planning, standardised safety pathways, workable payer arrangements and trained teams. Cell and gene therapy may be a scientific achievement, but its next phase will be judged in the ordinary machinery of hospitals: schedules, checklists, records, budgets and people.